Thalidomide: Mechanisms of action

International Reviews of Immunology

Volumn 27, Issue 3, 2008, Pages 111-135

  Paravar, Taraneh ^a   Lee, Delphine J ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Anti neoplastic agents; Immunosuppressive agents; Thalidomide

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD31 ANTIGEN; CD86 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEFENSIN; ELASTASE; GAMMA INTERFERON; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; LACTOFERRIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYSOZYME; MATRIX METALLOPROTEINASE; PLACEBO; PROSTAGLANDIN E2; T LYMPHOCYTE RECEPTOR; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; APHTHOUS STOMATITIS; APHTHOUS ULCER; APOPTOSIS; B LYMPHOCYTE; BEHCET DISEASE; BURN; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; EPIDERMIS; ERYTHEMA NODOSUM LEPROSUM; EXTRACELLULAR MATRIX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INNATE IMMUNITY; MEDIATOR; MELANOMA; METASTASIS; MOUTH ULCER; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; OFF LABEL DRUG USE; PANCREATITIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TISSUE REGENERATION; TUBERCULOSIS; TUMOR GROWTH; TUMOR IMMUNITY; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ERYTHEMA NODOSUM; HUMANS; IMMUNE SYSTEM; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; THALIDOMIDE;

EID: 42549163458     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.1080/08830180801911339     Document Type: Review

References (114)

1. G.W. Mellin, and M. Katzenstein, The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N. Engl. J. Med., 267: 1184-1192, 1962.
2. S. Tseng, G. Pak, K. Washenik, M.K. Pomeranz, and J.L. Shupack, Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol., 35:6, 969-979, 1996.
3. S.J. Matthews and McCoy, C. Thalidomide: a review of approved and investigational uses. Clin. Ther., 25: 342-395, 2003.
4. W. Lenz and K. Knapp, [Thalidomide embryopathy.]. Dtsch. Med. Wochenschr., 87: 1232-1242, 1962.
5. W.G. McBride, Thalidomide embryopathy. Teratology, 16: 79-82, 1977.
6. J. Sheskin, Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther., 40: 303-306, 1965.
7. J.B. Zeldis, B.A. Williams, S.D. Thomas, and M.E. Elsayed, S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther., 21: 319-330, 1999.
8. J.J. Wu, D.B. Huang, K.R. Pang, S. Hsu, and S.K. Tyring, Thalidomide: dermatological indications, mechanisms of action and side-effects. Br. J. Dermatol., 153: 254-273, 2005.
9. S.K. Teo, D.I. Stirling, and J.B. Zeldis, Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov. Today, 10: 107-114, 2005.
10. M.E. Blam, R.B. Stein, and G.R. Lichtenstein, Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am. J. Gastroenterol., 96: 1977-1997, 2001.
11. P. Aukrust, A. Yndestad, J.K. Damas, T. Ueland, E. Oie, and Gullestad, L. Potential mechanisms of benefit with thalidomide in chronic heart failure. Am. J. Cardiovasc. Drugs, 7: 127-134, 2007.
12. D. Tweedie, K. Sambamurti, and N.H. Greig, TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res., 4: 375-378, 2007.
13. M.R. Nasca, O'E.A. Toole, P. Palicharla, D.P. West, and D.T. Woodley, Thalidomide increases human keratinocyte migration and proliferation. J. Invest. Dermatol., 113: 720-724, 1999.
14. J.M. Schroder, Chemotactic cytokines in the epidermis. Exp. Dermatol., 1: 12-19, 1992.
15. R.L. Barnhill, N.J. Doll, L.E. Millikan, and R.C. Hastings, Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J. Am. Acad. Dermatol., 11: 814-819, 1984.
16. S. Dunzendorfer, P. Schratzberger, N. Reinisch, C.M. Kahler, and C.J. Wiedermann, Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium. Naunyn Schmiedebergs Arch. Pharmacol., 356: 529-535, 1997.
17. H. Nielsen and N.H. Valerius, Thalidomide enhances superoxide anion release from human polymorphonuclear and mononuclear leukocytes. Acta Pathol. Microbiol. Immunol. Scand.[C.], 94: 233-237, 1986.
18. N.P. Juffermans, A. Verbon, M.J. Schultz, C.E. Hack, van S.J. Deventer, Speelman, P. and P.T. van der, Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens. Antimicrob. Agents Chemother., 45: 1547-1549, 2001.
19. F. Payvandi, L. Wu, M. Haley, P.H. Schafer, L.H. Zhang, R.S. Chen, G.W. Muller, and D.I. Stirling, Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol., 230: 81-88, 2004.
20. J. Fujita, J.R. Mestre, J.B. Zeldis, K. Subbaramaiah, and A.J. Dannenberg, Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res., 7: 3349-3355, 2001.
21. S.H. Jin, T.I. Kim, K.M. Yang, and W.H. Kim, Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. Eur. J. Pharmacol., 558: 14-20, 2007.
22. E.P. Sampaio, E.N. Sarno, R. Galilly, Z.A. Cohn, and Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med., 173: 699-703, 1991.
23. T.L. Rowland, S.M. McHugh, J. Deighton, P.W. Ewan, R.J. Dearman, and Kimber, I. Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone. Immunol. Lett., 68: 325-332, 1999.
24. J.L. Tavares, A. Wangoo, P. Dilworth, B. Marshall, S. Kotecha, and R.J. Shaw, Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir. Med., 91: 31-39, 1997.
25. Q. Ye, B. Chen, Z. Tong, S. Nakamura, R. Sarria, U. Costabel, and Guzman, J. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur. Respir. J., 28: 824-831, 2006.
26. L. Deng, W. Ding, and R.D. Granstein, Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J. Invest Dermatol., 121: 1060-1065, 2003.
27. J.K. Ryu, and J.G. McLarnon, Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. Neurobiol. Dis., 29(2): 254-266, 2007.
28. C. Malazdrewich, P. Thumbikat, M.S. Abrahamsen, and S.K. Maheswaran, Pharmacological inhibition of Mannheimia haemolytica lipopolysaccharide and leukotoxin-induced cytokine expression in bovine alveolar macrophages. Microb. Pathog., 36: 159-169, 2004.
29. L.G. Corral, P.A. Haslett, G.W. Muller, R. Chen, L.M. Wong, C.J. Ocampo, R.T. Patterson, D.I. Stirling, and Kaplan, G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol., 163: 380-386, 1999.
30. A.L. Moreira, E.P. Sampaio, A. Zmuidzinas, P. Frindt, K.A. Smith, and G. Kaplan, Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med., 177: 1675-1680, 1993.
31. Y.S. Kim, J.S. Kim, H.C. Jung, and I.S. Song, The effects of thalidomide on the stimulation of NF-kappaB activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line. Mol. Cells, 17: 210-216, 2004.
32. J.A. Keifer, D.C. Guttridge, B.P. Ashburner, and A.S. Baldwin, Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem., 276: 22382-22387, 2001.
33. B.E. Turk, H. Jiang, and J.O. Liu, Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc. Natl. Acad. Sci. U.S.A, 93: 7552-7556, 1996.
34. E.P. Sampaio, A.L. Moreira, E.N. Sarno, A.M. Malta, and G. Kaplan, Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J. Exp. Med., 175: 1729-1737, 1992.
35. E.P. Sampaio, G. Kaplan, A. Miranda, J.A. Nery, C.P. Miguel, S.M. Viana, and E.N. Sarno, The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis., 168: 408-414, 1993.
36. J.M. Tramontana, U. Utaipat, A. Molloy, P. Akarasewi, M. Burroughs, S. Makonkawkeyoon, B. Johnson, J.D. Klausner, W. Rom, and Kaplan, G. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med., 1: 384-397, 1995.
37. J.D. Klausner, S. Makonkawkeyoon, P. Akarasewi, K. Nakata, W. Kasinrerk, L. Corral, R.L. Dewar, H.C. Lane, V.H. Freedman, and G. Kaplan, The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 11: 247-257, 1996.
38. G.S. Xiong, S.M. Wu, Z.H. Wang, J.Z. Mo, and S.D. Xiao, Effects of thalidomide in experimental models of post-endoscopic retrograde cholangiopancreatography pancreatitis. J. Gastroenterol. Hepatol., 22: 371-376, 2007.
39. G. Malleo, E. Mazzon, T. Genovese, Di R. Paola, C. Muia, C. Crisafulli, A.K. Siriwardena, and Cuzzocrea, S. Effects of thalidomide in a mouse model of cerulein-induced acute pancreatitis. Shock, 29(1): 89-97, 2007.
40. P.A. Haslett, P. Roche, C.R. Butlin, M. Macdonald, N. Shrestha, R. Manandhar, J. Lemaster, R. Hawksworth, M. Shah, A.S. Lubinsky, M. Albert, J. Worley, and Kaplan, G. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J. Infect. Dis., 192: 2045-2053, 2005.
41. S.J. Oliver, T. Kikuchi, J.G. Krueger, and G. Kaplan, Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin. Immunol., 102: 225-236, 2002.
42. J.M. Jacobson, J.S. Greenspan, J. Spritzler, N. Ketter, J.L. Fahey, J.B. Jackson, L. Fox, M. Chernoff, A.W. Wu, L.A. MacPhail, G.J. Vasquez, and D.A. Wohl, Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Engl. J. Med., 336: 1487-1493, 1997.
43. L. Gullestad, T. Ueland, J.G. Fjeld, E. Holt, T. Gundersen, K. Breivik, M. Folling, A. Hodt, R. Skardal, J. Kjekshus, A. Andreassen, E. Kjekshus, R. Wergeland, A. Yndestad, S.S. Froland, A.G. Semb, and P. Aukrust, Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation, 112: 3408-3414, 2005.
44. M. Eski, I. Sahin, M. Sengezer, M. Serdar, and A. Ifran, Thalidomide decreases the plasma levels of IL-1 and TNF following burn injury: Is it a new drug for modulation of systemic inflammatory response. Burns, 34(1) 104-108, 2008.
45. G.B. Rodrigues, G.F. Passos, Di G. Giunta, C.P. Figueiredo, E.B. Rodrigues, A. Grumman, Jr., R. Medeiros, and J.B. Calixto, Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats. Exp. Eye Res., 84: 553-560, 2007.
46. A.L. Moreira, Tsenova-L. Berkova, J. Wang, P. Laochumroonvorapong, S. Freeman, V.H. Freedman, and Kaplan, G. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tuber. Lung Dis., 78: 47-55, 1997.
47. T.L. Rowland, S.M. McHugh, J. Deighton, R.J. Dearman, P.W. Ewan, and I. Kimber, Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology, 40: 11-20, 1998.
48. C. Tabata, R. Tabata, Y. Kadokawa, S. Hisamori, M. Takahashi, M. Mishima, T. Nakano, and H. Kubo, Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J. Immunol., 179: 708-714, 2007.
49. D. Gupta, S.P. Treon, Y. Shima, T. Hideshima, K. Podar, Y.T. Tai, B. Lin, S. Lentzsch, F.E. Davies, D. Chauhan, R.L. Schlossman, P. Richardson, P. Ralph, L. Wu, F. Payvandi, G. Muller, D.I. Stirling, and K.C. Anderson, Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 15: 1950-1961, 2001.
50. F. Caligaris-Cappio, L. Bergui, M.G. Gregoretti, G. Gaidano, M. Gaboli, M. Schena, A.Z. Zallone, and P.C. Marchisio, 'Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood, 77: 2688-2693, 1991.
51. F.E. Davies, N. Raje, T. Hideshima, S. Lentzsch, G. Young, Y.T. Tai, B. Lin, K. Podar, D. Gupta, D. Chauhan, S.P. Treon, P.G. Richardson, R.L. Schlossman, G.J. Morgan, G.W. Muller, D.I. Stirling, and K.C. Anderson, Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98: 210-216, 2001.
52. A. Kawamata, D. Ito, T. Odani, T. Isobe, M. Iwase, M. Hatori, and M. Nagumo, Thalidomide suppresses melanoma growth by activating natural killer cells in mice. Oncol. Rep., 16: 1231-1236, 2006.
53. N. Mitsiades, C.S. Mitsiades, V. Poulaki, D. Chauhan, P.G. Richardson, T. Hideshima, N.C. Munshi, S.P. Treon, and K.C. Anderson, Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99: 4525-4530, 2002.
54. Y.C. Lin, C.T. Shun, M.S. Wu, and C.C. Chen, A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin. Cancer Res., 12: 7165-7173, 2006.
55. S. Majumdar, B. Lamothe, and B.B. Aggarwal, Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J. Immunol., 168: 2644-2651, 2002.
56. A.L. Moreira, L.G. Corral, W. Ye, B. Johnson, D. Stirling, G.W. Muller, V.H. Freedman, and G. Kaplan, Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res. Hum. Retroviruses, 13: 857-863, 1997.
57. S.H. Jin, T.I. Kim, D.S. Han, S.K. Shin, and W.H. Kim, Thalidomide suppresses the interleukin 1beta-induced NFkappaB signaling pathway in colon cancer cells. Ann. N.Y. Acad. Sci., 973: 414-418, 2002.
58. K. Ebnet, and D. Vestweber, Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines. Histochem. Cell Biol., 112: 1-23, 1999.
59. H. Geitz, S. Handt, and K. Zwingenberger, Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 31: 213-221, 1996.
60. A.C. Nogueira, R. Neubert, H. Helge, and D. Neubert, Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci., 55: 77-92, 1994.
61. B. Settles, A. Stevenson, K. Wilson, C. Mack, T. Ezell, M.F. Davis, and L.D. Taylor, Down-regulation of cell adhesionmolecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol. Biol.(Noisy.-le-grand), 47: 1105-1114, 2001.
62. W. Auttachoat, J.F. Zheng, R.P. Chi, A. Meng, and T.L. Guo, Differential surface expression of CD18 and CD44 by neutrophils in bone marrow and spleen contributed to the neutrophilia in thalidomide-treated female B6C3F1 mice. Toxicol. Appl. Pharmacol., 218: 227-237, 2007.
63. P. Lv, H.S. Luo, X.P. Zhou, Y.J. Xiao, S.C. Paul, X.M. Si, and Y.H. Zhou, Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch. Med. Res., 38: 15-27, 2007.
64. P. Lv, S.C. Paul, Y. Xiao, Liu, S. and Luo, H. Effects of thalidomide on the expression of adhesion molecules in rat liver cirrhosis. Mediators. Inflamm., 4: 9325, 2006.
65. M. Faure, J. Thivolet, and M. Gaucherand, Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch. Dermatol. Res., 269: 275-280, 1980.
66. S. Dunzendorfer, M. Herold, and C.J. Wiedermann, Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide. Immunopharmacology, 43: 59-64, 1999.
67. T. Yagyu, H. Kobayashi, H. Matsuzaki, K. Wakahara, T. Kondo, N. Kurita, H. Sekino, K. Inagaki, M. Suzuki, N. Kanayama, and T. Terao, Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J. Clin. Endocrinol. Metab, 90: 3017-3021, 2005.
68. J.R. Lokensgard, S. Hu, E.M. van Fenema, W.S. Sheng, and P.K. Peterson, Effect of thalidomide on chemokine production by human microglia. J. Infect. Dis., 182: 983-987, 2000.
69. H. Kuniyasu, P. Troncoso, D. Johnston, C.D. Bucana, E. Tahara, I.J. Fidler, and C.A. Pettaway, Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin. Cancer Res., 6: 2295-2308, 2000.
70. E. Efstathiou, P. Troncoso, S. Wen, K.A. Do, C.A. Pettaway, L.L. Pisters, T.J. McDonnell, and C.J. Logothetis, Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin. Cancer Res., 13: 1224-1231, 2007.
71. Janowska-A. Wieczorek, A. Matsuzaki, and A. Marquez, The hematopoietic microenvironment: matrix metalloproteinases in the hematopoietic microenvironment. Hematol., 4: 515-527, 2000.
72. M. Gelati, E. Corsini, S. Frigerio, B. Pollo, G. Broggi, D. Croci, A. Silvani, Boiardi, A. and Salmaggi, A. Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. J. Neurooncol., 64: 193-201, 2003.
73. R. Invernizzi, E. Travaglino, De M. Amici, S. Brugnatelli, I. Ramajoli, B. Rovati, C. Benatti, and E. Ascari, Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. Leuk. Res., 29: 641-647, 2005.
74. M. Wong, L. Staszewsky, R. Latini, S. Barlera, R. Glazer, N. Aknay, A. Hester, I. Anand, and J.N. Cohn, Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J. Am. Coll. Cardiol., 43: 2022-2027, 2004.
75. E.J. Shannon, R.O. Miranda, M.J. Morales, and R.C. Hastings, Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand. J. Immunol., 13: 553-562, 1981.
76. N.A. Karrow, J.A. McCay, R.D. Brown, D.L. Musgrove, D.A. Pettit, A.E. Munson, D.R. Germolec, and K.L. White, Jr. Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. Toxicol. Appl. Pharmacol., 165: 237-244, 2000.
77. M. Vilanova, A. Ribeiro, J. Carneiro, and M. Arala-Chaves, The effects of thalidomide treatment on autoimmune-prone NZB and MRL mice are consistent with stimulation of the central immune system. Scand. J. Immunol., 40: 543-548, 1994.
78. Arala-M. Chaves, M. Vilanova, A. Ribeiro, and J. Pinto, Immunostimulatory effect of thalidomide in normal C57BL/6 mice is compatible with stimulation of a highly connected central immune system. Scand. J. Immunol., 40: 535-542, 1994.
79. S.M. Gad, E.J. Shannon, W.A. Krotoski, and R.C. Hastings, Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr. Rev., 56: 35-39, 1985.
80. E.J. Shannon, M. Ejigu, H.S. Haile-Mariam, T.Y. Berhan, and G. Tasesse, Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Lepr. Rev., 63: 5-11, 1992.
81. R.J. Keenan, G. Eiras, G.J. Burckart, R.S. Stuart, R.L. Hardesty, G. Vogelsang, B.P. Griffith, and A. Zeevi, Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. Transplantation, 52: 908-910, 1991.
82. P.A. Haslett, L.G. Corral, M. Albert, and G. Kaplan, Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+subset. J. Exp. Med., 187: 1885-1892, 1998.
83. S.M. McHugh, I.R. Rifkin, J. Deighton, A.B. Wilson, P.J. Lachmann, C.M. Lockwood, and P.W. Ewan, The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol., 99: 160-167, 1995.
84. S.J. Oliver, A. Moreira, and G. Kaplan, Immune stimulation in scleroderma patients treated with thalidomide. Clin. Immunol., 97: 109-120, 2000.
85. A. Verbon, N.P. Juffermans, P. Speelman, van S.J. Deventer, ten I.J. Berge, H.J. Guchelaar, and van P.T. der, A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob. Agents Chemother., 44: 2286-2290, 2000.
86. E.J. Shannon and F. Sandoval, Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology, 31: 109-116, 1995.
87. E. Shannon, A. Aseffa, G. Pankey, F. Sandoval, and B. Lutz, Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood. Immunopharmacology, 46: 175-179, 2000.
88. M. Mohty, A.M. Stoppa, D. Blaise, D. Isnardon, J.A. Gastaut, D. Olive, and B. Gaugler, Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J. Leukoc. Biol., 72: 939-945, 2002.
89. R.H. DeKruyff, R.S. Gieni, and D.T. Umetsu, Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J. Immunol., 158: 359-366, 1997.
90. D.R. Moller, M. Wysocka, B.M. Greenlee, X. Ma, L. Wahl, D.A. Flockhart, G. Trinchieri, and C.L. Karp, Inhibition of IL-12 production by thalidomide. J. Immunol., 159: 5157-5161, 1997.
91. P.A. Haslett, J.D. Klausner, S. Makonkawkeyoon, A. Moreira, P. Metatratip, B. Boyle, W. Kunachiwa, N. Maneekarn, P. Vongchan, L.G. Corral, T. Elbeik, Z. Shen, and G. Kaplan, Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res. Hum. Retroviruses, 15: 1169-1179, 1999.
92. A.T. Carvalho, H. Souza, A.J. Carneiro, Castelo-M. Branco, K. Madi, A. Schanaider, F. Silv, Pereira F.A. Junior, M.G. Pereira, C. Tortori, I. Dines, J. Carvalho, E. Rocha, and C. Elia, Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. World J. Gastroenterol., 13: 2166-2173, 2007.
93. J. Bauditz, S. Wedel, and H. Lochs, Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut, 50: 196-200, 2002.
94. T. Hideshima, D. Chauhan, Y. Shima, N. Raje, F.E. Davies, Y.T. Tai, S.P. Treon, B. Lin, R.L. Schlossman, P. Richardson, G. Muller, D.I. Stirling, and K.C. Anderson, Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96: 2943-2950, 2000.
95. A. Dmoszynska, M. Podhorecka, J. Manko, Bojarska-A. Junak, J. Rolinski, and D. Skomra, The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. Neoplasma, 52: 175-181, 2005.
96. H.R. Gockel, A. Lugering, J. Heidemann, M. Schmidt, W. Domschke, T. Kucharzik, and N. Lugering, Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J. Immunol., 172: 5103-5109, 2004.
97. D.R. Green and J.C. Reed, Mitochondria and apoptosis. Science, 281: 1309-1312, 1998.
98. G.J. Du, H.H. Lin, Q.T. Xu, and M.W. Wang, Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul. Pharmacol., 43: 112-119, 2005.
99. J. Folkman, Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
100. R. J. D'Amato, M.S. Loughnan, E. Flynn, and J. Folkman, Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A, 91: 4082-4085, 1994.
101. B.M. Kenyon, Browne, F. and R. J. D'Amato, Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res., 64: 971-978, 1997.
102. J. Komorowski, H. Jerczynska, A. Siejka, P. Baranska, H. Lawnicka, Z. Pawlowska, and H. Stepien, Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci, 78(22): 2558-2563, 2006.
103. G.P. Vasvari, G. Dyckhoff, F. Kashfi, B. Lemke, J. Lohr, B.M. Helmke, V. Schirrmacher, P.K. Plinkert, P. Beckhove, and C.C. Herold-Mende, Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. Int. J. Cancer, 121: 1697-1704, 2007.
104. A.L. Moreira, D.R. Friedlander, B. Shif, G. Kaplan, and D. Zagzag, Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J. Neurooncol., 43: 109-114, 1999.
105. T. Yabu, H. Tomimoto, Y. Taguchi, S. Yamaoka, Y. Igarashi, and T. Okazaki, Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1- phosphate. Blood, 106: 125-134, 2005.
106. W.T. Bellamy, L. Richter, Y. Frutiger, and T.M. Grogan, Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res., 59: 728-733, 1999.
107. L. Zhang, S.L. Chen, W.M. Chen, and J.W. Liu, [The interaction of vascular endothelial growth factor and interleukin-6 in multiple myeloma.]. Zhonghua Nei Ke. Za Zhi., 44: 85-88, 2005.
108. A. Vacca, C. Scavelli, V. Montefusco, Di G. Pietro, A. Neri, M. Mattioli, S. Bicciato, B. Nico, D. Ribatti, F. Dammacco, and P. Corradini, Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J. Clin. Oncol., 23: 5334-5346, 2005.
109. S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson, P. Eddlemon, N. Munshi, E. Anaissie, C. Wilson, M. Dhodapkar, J. Zeddis, and B. Barlogie, Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 341: 1565-1571, 1999.
110. O. Arrieta, P. Guevara, J. Tamariz, D. Rembao, E. Rivera, and J. Sotelo, Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma. Int. J. Exp. Pathol., 83: 99-104, 2002.
111. K. Dredge, A.G. Dalgleish, and J.B. Marriott, Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs, 14: 331-335, 2003.
112. Aragon-J.B. Ching, H. Li, E.R. Gardner, and W.D. Figg, Thalidomide analogues as anticancer drugs. Rec. Patents. Anticancer Drug Discov., 2: 167-174, 2007.
113. K. Dredge, J.B. Marriott, and A.G. Dalgleish, Immunological effects of thalidomide and its chemical and functional analogs. Crit. Rev. Immunol., 22:5-6, pp. 425-437, 2002.
114. S.K. Teo, Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS. J., 7: E14-E19, 2005.